Jaguar8 commented on a stock · Nov 21, 2024 21:54

NEWS

GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

GRI Bio presented positive preclinical data for GRI-0621, its lead program targeting Idiopathic Pulmonary Fibrosis (IPF), at the 8th Annual Antifibrotic Drug Development Summit. The data showed that GRI-0621 reduces inflammation and fibrotic drivers in IPF. Key findings demonstrated increased iNKT cell activity correlating with fibrosis progression, while GRI-0621 administration inhibited pro-inflammatory cytokines and decreased neutrophil accumulation. The company is currently conducting a Phase 2a clinical trial for IPF treatment, with interim data expected in Q1 2025 and topline results in Q2 2025.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more